神经生长因子与溴隐亭：人类溴隐亭抵抗性催乳素瘤的序贯疗法
Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
作者信息
Missale C, Losa M, Boroni F, Giovanelli M, Balsari A, Spano P F
机构信息
Department of Biomedical Sciences and Biotechnology, School of Medicine, University of Brescia, Italy.
出版信息
Br J Cancer. 1995 Dec;72(6):1397-9. doi: 10.1038/bjc.1995.520.
Nerve growth factor (NGF) administration to athymic mice with transplanted human bromocriptine-resistant prolactinoma, results in the expression of dopamine D-2 receptors in the tumour and restores sensitivity to subsequent treatment with bromocriptine, which then produces normalisation of plasma prolactin and tumour regression. Sequential administration of NGF and bromocriptine thus may be a promising therapy for patients refractory to bromocriptine.
给移植了人溴隐亭抵抗性催乳素瘤的无胸腺小鼠注射神经生长因子（NGF），会导致肿瘤中多巴胺D-2受体的表达，并恢复对后续溴隐亭治疗的敏感性，进而使血浆催乳素正常化并使肿瘤消退。因此，对溴隐亭难治的患者，序贯给予NGF和溴隐亭可能是一种有前景的治疗方法。
Zotero 插件